Shares of Atara Biotherapeutics Inc. (NASDAQ:ATRA) were down 8.8% on Monday . The stock traded as low as $21.80 and last traded at $22.68, with a volume of 243,345 shares trading hands. The stock had previously closed at $24.87.

Several analysts have recently weighed in on ATRA shares. Jefferies Group reaffirmed a “buy” rating and issued a $22.00 target price (down previously from $26.00) on shares of Atara Biotherapeutics in a report on Monday, May 9th. Canaccord Genuity reaffirmed a “buy” rating on shares of Atara Biotherapeutics in a report on Tuesday, June 7th. JMP Securities reaffirmed a “buy” rating on shares of Atara Biotherapeutics in a report on Saturday, July 9th. Finally, Zacks Investment Research downgraded shares of Atara Biotherapeutics from a “hold” rating to a “sell” rating in a report on Tuesday, May 3rd. Two analysts have rated the stock with a sell rating, one has assigned a hold rating and five have given a buy rating to the company’s stock. The stock has an average rating of “Hold” and an average price target of $27.71.

The company has a 50 day moving average price of $22.60 and a 200-day moving average price of $19.16. The company’s market cap is $647.89 million.

Atara Biotherapeutics (NASDAQ:ATRA) last issued its earnings results on Thursday, May 5th. The company reported ($0.58) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.55) by $0.03. During the same period in the prior year, the business earned ($0.42) EPS. On average, analysts forecast that Atara Biotherapeutics Inc. will post ($2.64) EPS for the current year.

In related news, CEO Isaac E. Ciechanover sold 12,000 shares of the stock in a transaction dated Wednesday, June 8th. The shares were sold at an average price of $20.53, for a total value of $246,360.00. Following the sale, the chief executive officer now owns 223,228 shares of the company’s stock, valued at approximately $4,582,870.84. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, COO Gad Soffer sold 5,427 shares of the stock in a transaction dated Tuesday, May 17th. The stock was sold at an average price of $15.91, for a total transaction of $86,343.57. Following the completion of the sale, the chief operating officer now directly owns 138,125 shares in the company, valued at approximately $2,197,568.75. The disclosure for this sale can be found here.

An institutional investor recently raised its position in Atara Biotherapeutics stock. Jennison Associates boosted its position in Atara Biotherapeutics Inc. (NASDAQ:ATRA) by 40.8% during the third quarter, according to its most recent 13F filing with the SEC. The fund owned 844,180 shares of the company’s stock after buying an additional 244,695 shares during the period. Jennison Associates owned 2.95% of Atara Biotherapeutics worth $26,541,000 as of its most recent filing with the SEC.

Atara Biotherapeutics, Inc is a clinical-stage biopharmaceutical company. Its segment is the business of developing and commercializing therapeutics. It has approximately two groups of product candidates, such as allogeneic or third-party derived antigen-specific T-cells, and molecularly targeted biologics.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.